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Sentinel lymph node biopsy
Not yet standard of care for melanoma
Editor—Kell and Kerin wrote about senti-
nel lymph node biopsy in breast cancer and
melanoma.1 This is a staging procedure with
a well established role in breast cancer,
reducing the need for dissection of the axil-
lary node. The indications and advantages
for sentinel lymph node biopsy in
melanoma are not confirmed, and it is
certainly not the established treatment
implied in the editorial.2
Sentinel node status in melanoma is
indeed the best staging and prognostic indi-
cator: patients with negative results have a
better prognosis then those with positive
results. However, there is no evidence from
randomised clinical trials that completion
lymphadenectomy (sometimes known as
selective lymphadenectomy) in patients with
positive sentinel node biopsies offers any
survival advantage. Neither is there any
adjuvant therapy that can influence the
natural history and benefit patients who are
sentinel node positive.3 Concern has
recently been raised about the possible
increased incidence of local and in-transit
recurrence in patients with positive sentinel
nodes who undergo completion lym-
phadenectomy.4 This iatrogenic complica-
tion carries an ominous prognosis and is
probably explained by lymphatic obstruc-
tion and entrapment of melanoma cells in
transit to the regional nodes.
The final decision for or against sentinel
lymph node biopsy in melanoma must await
the result of a multicentre selective lym-
phadenectomy trial, which will not be
published before 2006.5 Until then, patients
deserve to be informed that sentinel lymph
node biopsy in melanoma is an investiga-
tional procedure with an unknown out-
come; the significance of a possibly
increased incidence of local or in-transit
recurrence should be included when obtain-
ing informed consent.
A degree of editorial balance in the
literature should be encouraged, rather than
the present unbridled enthusiasm for an
attractive but unproved concept.
J Meirion Thomas consultant surgical oncologist
sarcoma@mac.com
Matthew A Clark consultant surgical oncologist
Royal Marsden Hospital Melanoma and Sarcoma
Unit, London SW3 6JJ
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Optimum method remains to be
determined
Editor—Kell and Kerin report on the
current status of sentinel lymph node biopsy
in the surgical treatment of breast cancer
and melanoma.1 They say that the detection
of occult malignancy in lymph nodes in
breast cancer signifies a worse prognosis
and that the rapid intraoperative detection
of malignant cells by immunocytochemistry
will vitalise sentinel node biopsy—both
assertions may be premature. Although a
number of earlier studies have shown a
worse prognosis, a more recent study using
multivariate analysis has indicated that
occult metastases are of no independent
prognostic importance.2
The optimum method by which lymph
nodes removed in the course of breast
cancer surgery should be examined, includ-
ing the utility of immunocytochemistry,
remains to be determined. Touch imprint
cytology is a reliable method for the
detection of carcinoma cells, but may not
reliably discriminate between macrometas-
tases (deposits > 2 mm), micrometastases
(deposits < 2 mm), and small numbers of
individual tumour cells affecting the periph-
eral sinus of a lymph node.3 Further studies,
preferably with large numbers of patients
and adequate follow up, will be required
before these techniques enter routine
practice.
Ervine D Long consultant histopathologist
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Sentinel node technique has drawbacks
Editor—Among the possible drawbacks of
sentinel node biopsy, discussed by Kell and
Kerin,1 is the risk of false positive findings
because of reactive lymph node swelling in
the biopsy site. Periodic follow up of the
sampled lymph node area has become a
common practice after sentinel node biopsy,
mostly based on palpation and ultrasonog-
raphy. Swelling of axillary or inguinal lymph
nodes reactive to sentinel node biopsy is
likely to occur; a reaction in these sites is a
common event, even after lesser injuries.
Unfortunately, both palpation and ultra-
sonography are poorly accurate in assessing
enlarged nodes, and false positive reports
are likely to occur: fine needle aspiration
may help, if positive, but considering that in
these cases a greater diagnostic aggressive-
ness is expected, a false positive assessment
might end in further surgical biopsy of the
lymph node. A more aggressive surveillance
regimen is expected in patients undergoing
sentinel node biopsy, as is a higher
frequency of false positive reports and
unnecessary invasive procedures.
This possible negative effect is rarely
addressed in the literature, although it might
substantially reduce the benefits of sentinel
node biopsy, a technique aimed uniquely at
improving quality of life. Studies aiming to
show the cost effectiveness of sentinel node
biopsy should mainly address quality of life
as the end point, and the frequency of inva-
sive procedures to assess false positive
findings at periodic follow up should be a
variable carefully taken into account.
Stefano Ciatto head
Department Diagnostic Imaging, Centro per lo
Studio e la Prevenzione Oncologica, Viale Volta
171, I-50131, Florence, Italy
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Authors’ reply
Editor—As we said, numerous issues about
sentinel lymph node biopsy will be answered
only by prospective clinical trials. The
technique is a very important minimally inva-
sive predictive prognostic indicator in breast
cancer and melanoma. In these conditions
performing either no lymphatic surgery or
lymphatic clearance surgery on all patients
would be neither evidence based nor safe.
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We agree with Thomas and Clark that
there is a degree of nihilistic predetermina-
tion in melanoma owing to the lack of an
appropriate therapeutic intervention, but
the concept of sentinel lymph node biopsy
leading to in transit and more aggressive
local disease is counterintuitive and not sup-
ported by current literature.
We agree with Long and Read in princi-
ple, though we have quoted the current
seminal article on sentinel lymph node
biopsy micrometastases, which examines
almost 1000 patients compared with a more
recent paper with fewer than half this
number.1 2 The definitive answer will hope-
fully be answered by ACOSOG Z10, which
will examine the clinical outcome of breast
cancer patients with sentinel lymph node
biopsy micrometastases.3
In our experience of performing several
hundred sentinel lymph node biopsies for
both melanoma and breast cancer we have
not found false positive lymphadenopathy
after the biopsy to be a real clinical concern.
We believe that there is no evidence in the
literature to support this either.
Patients should be given the most
accurate prognostic information available.
The evidence base for widespread utilisation
of the best prognostic test (sentinel lymph
node biopsy) has led to the use of this tech-
nique in north America and many other
countries; enthusiasm is beginning to grow
in the United Kingdom.
Malcolm R Kell senior specialist registrar
malcolmkell@eircom.net
Michael J Kerin consultant surgeon
Department of Surgery, National Breast Cancer
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Review of instruments for peer
assessment of physicians
Clinics with peers keep you on the
straight and narrow. . .
Editor—Evans et al raise several points in
their article reviewing methods of peer
assessment.1
Firstly, joint clinics are excellent for
observing colleagues—and being observed
by them—in genuine clinical situations. I
regularly hold joint clinics with colleagues
from overlapping specialties, such as genet-
ics, neurology, ophthalmology, etc. I learn
new ways of communicating with patients
and families: opening the consultation,
giving explanations and (bad) news. Oppor-
tunities exist to question colleagues at the
time of the consultation—for example, why
are you doing or not doing an investigation?
It is non-threatening, constructive, and leads
to reflective discussion.
Secondly, 360 degree appraisals are
popular but have not been validated.2 Any
doctor worth their salt will challenge the sta-
tus quo. We should ask difficult questions of
ourselves (especially), colleagues, other
health professionals, administrators, and
sometimes patients and parents. Fear of get-
ting poor reports will mean that either the
appraisal forms are given to those who like
us or we will be subdued in challenging
poor, lazy, or inefficient practice.
Thirdly, doctors’ “poor communication”
was raised.3 No group in the health service
sees the number of patients, works the
hours, and makes the number of decisions
of consequence that doctors do. Doctors
give difficult, unpleasant, complicated infor-
mation to people who often feel upset, anx-
ious, angry, and guilty. What is remarkable is
how often doctors communicate well under
those circumstances rather than badly. The
doctor-patient relationship is two way. It is
specious to assume that poor communica-
tion would be reduced or eliminated if the
doctor had better communication skills.
Charles Essex consultant neurodevelopmental
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Child Development Unit, Gulson Hospital,
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. . . and our impact on one another is
important
Editor—Evans et al reviewed instruments
for peer assessment of physicians.1 Decades
of experience helping healthcare profes-
sionals learn how to seek, give, receive, and
process feedback has led to several conclu-
sions.2 Rigorous psychometric techniques
have little place when what is being explored
is the impact human beings have on one
another when they interact face to face.
The primary form of validity that really
matters is face validity, specifically because the
judgments are subjective—the “subjects” are
human beings. This same fact explains the
“poor agreement between observers of the
same event” when “humanistic qualities” are
of concern. The “observer,” after all, is not the
person experiencing the event. Furthermore,
even when a person exhibits the same behav-
iour towards two separate people, he or she
can, and, as our own research documents,
often does, experience the behaviour differ-
ently. As well they should, for they, too, are
different human beings.
Perhaps in trying to be “scientifically rig-
orous” the essential nature of human
interactions is being missed. We are not,
however, arguing against the use of instru-
ments. Rather, we are emphasising that the
most useful instrument will be one that ena-
bles two people to get a clear, non-
judgmental, behaviourally specific (versus
dealing with crucial but immeasurable and
judgmental qualities such as “honesty” and
“trust”) picture of the impact they are having
on one another. We highlight the word they
because our experience has been, and
increasing numbers of others are reporting,
that the current fad of anonymous aggre-
gated 360 degree assessments is, indeed,
iatrogenic. Faceless mechanisms that pur-
port to improve the quality of face-to-face
human encounters are an oxymoron.
Irwin M Rubin president
Temenos, 37 Kawananakoa Place, Honolulu, HI
96917, USA
temenos@lava.net
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Ginkgo biloba and
acetazolamide for acute
mountain sickness
Exclusion of high risk, low status groups
perpetuates discrimination and
inequalities
Editor—Gertsch et al report the results of a
randomised controlled trial of ginkgo biloba
and acetazolamide for acute mountain sick-
ness in trekkers in the Everest region of
Nepal.1 However, it is not clear why entry to
the study was restricted to non-Nepali
trekkers. Many Nepalis working in the
trekking industry in the Everest region are
not stereotypical. Sherpas who have lived
their whole life at altitude and are at similar,
if not greater, risk of acute mountain
sickness as Western trekkers (see www.port-
ersprogress.org). Although including Nepa-
lis at risk of acute mountain sickness in the
study would have entailed some additional
logistical arrangements, these should not be
beyond the abilities of a large, international
research team.
Studies such as this, which exclude high
risk, low status groups for no obvious
reason, perpetuate discrimination and
inequalities. Evidence is required on how to
prevent acute mountain sickness in all
groups, and not just rich Western tourists.
Jean Adams research fellow
School of Population and Health Sciences,
University of Newcastle upon Tyne, Newcastle upon
Tyne NE2 4HH
j.m.adams@ncl.ac.uk
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Bias in participants may underestimate
effectiveness of agents
Editor—In their randomised controlled
trial of gingko biloba and acetazolamide for
preventing acute mountain sickness Gertsch
et al do not include data on eligible trekkers
who declined enrolment.1 These data are
important as the trial participants may not
be representative of all non-Nepali trekkers.
A bias in participants may underestimate
the effectiveness of either
agent. This is particularly
important for gingko, which
is stated to be no more effec-
tive than placebo.
Many trekkers arriving in
Nepal will have established
views on drug treatments for
altitude sickness. Some will
already be in possession of
their drug of choice. Such
people are likely to refuse
randomisation to drug or
placebo and will therefore
have been excluded from the trial. If a
significant number of these had perceived
prior benefit from gingko, its effectiveness
will have been underestimated.
From the information provided it is
impossible to comment on the non-
effectiveness of gingko in preventing acute
mountain sickness.
Heather L Elphick specialist registrar, geriatric
medicine
Northern General Hospital, Sheffield S5 7AU
elphickdh@hotmail.com
David A Elphick specialist registrar, gastroenterology
Royal Hallamshire Hospital, Sheffield S10 2JF
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Editor—The recruitment of Western
trekkers in the prevention of high altitude ill-
ness trial (PHAIT) study was based on
logistics and practicality. Sherpas and other
Nepalis residing in or adjacent to the Everest
region and above 2000 m are highly resistant
to the effects of altitude and would thus be
poor research participants. Although many
Nepalis working in the Everest region reside
at altitudes below 1500 m (potentially eligible
research candidates), a fair proportion live in
higher regions that would make some degree
of acclimatisation likely.
Furthermore, many lowland dwelling
Nepalis working as porters will relocate
temporarily for the season to wait for work
at the airstrip in Lukla (2500 m), where tour-
ists begin their trek. Many will therefore
acclimatise en masse in the first weeks of the
season, providing a narrow window for
enrolment. One of us (BB) tried in 2001 to
study lowland porters as subjects but failed
to collect adequate data primarily because of
poor enrolment and a high rate of loss to
follow up. We agree that more evidence is
needed about the epidemiology and treat-
ment of altitude sickness in lowland Nepalis.
Excluding bias in clinical trials conducted
in the Everest region is inherently problem-
atic because of logistical issues unique to the
area. Healthy vacationing trekkers who
decline participation in a clinical trial are
often not interested in taking the time to pro-
vide further information. The argument
against bias in our model stems from the
large homogeneous cohort evaluated under
strict double blinding and in
agreement with CONSORT
guidelines, as well as the lack
of any differences within
groups or in comparing those
enrolled with those lost to fol-
low up.1 The failure to collect
data on those who chose not
to enrol in the trial is a weak-
ness of the PHAIT study and
was dealt with in a subsequent
clinical trial (B Basnyat and J
Gertsch, unpublished data;
see full reply on bmj.com).
Given these data, we are confident that
the PHAIT study is a fair and convincing test
of ginkgo’s efficacy under the conditions
tested.
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National screening programme
for chlamydia exists in England
Editor—The news article on the coverage of
chlamydia screening in England was disap-
pointing.1 Contrary to its suggestion that no
“formal” chlamydia screening programme in
England exists, the national chlamydia
screening programme in England was estab-
lished in 2002 after a successful pilot study in
Portsmouth and Wirral and publication of
the government’s national sexual health and
HIV strategy implementation plan.2 It is
currently the only such screening pro-
gramme in Europe (N Low, British Associa-
tion for Sexual Health–American Sexually
Transmitted Diseases Association spring
meeting, Bath, May 2004).
Over the past 18 months 26 local
chlamydia screening programmes have been
implemented in two phases across England,
covering over 25% of all primary care trusts.
A third phase of implementation will be
launched in the autumn of 2004. The
programme offers opportunistic screening to
women and men younger than 25 in a range
of settings outside genitourinary medicine.
National guidelines for screening have been
produced.3 The programme is guided by a
multidisciplinary steering committee and
operates within the framework of the national
screening committee. The first year’s annual
report will be published in autumn 2004.
By suggesting that screening is the only
effective intervention, the news article also
obscures the range of prevention activities
that are taking place concurrently. These
include implementation of the highly sensi-
tive nucleic acid amplification tests; public
education campaigns; the development of
rapid, near patient, diagnostic tests for
chlamydia; and allied research and evalua-
tion. No government indecision has
occurred in this matter.
The so called slow progress of imple-
mentation reflects the time taken to roll out
this complex public health programme, in a
considered manner, over five years—
precisely to avoid unmanaged growth. The
scale of the exercise is considerable, given
the unique nature of this programme, the
range of sites being included, and the
immense challenges of implementation in
the context of a changing NHS.
K A Fenton consultant epidemiologist
kevin.fenton@hpa.org.uk
D Scott LaMontagne epidemiologist
HIV and STI Department, Health Protection
Agency Communicable Disease Surveillance
Centre, London NW9 5EQ
Sarah Randall consultant, reproductive health
Ella Gordon Unit, St Mary’s Hospital, Portsmouth
PO3 6AF
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Discharge rates for suspected
acute coronary syndromes
Is morbidity or empowerment
increasing?
Editor—In their population based analysis
Murphy et al reported a marked increase in
morbidity rates for suspected acute coronary
syndromes between 1990 and 2000.1 How-
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Full reply is available on bmj.com
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ever, we need to eliminate all reasonable
doubt that the trend represents an actual rise
and is not simply the result of empowerment
of the population, enabled to recognise
symptoms and enforce their rights better.
For example, among “new fashioned”
elderly people, this factor may contribute to
the reported rise in morbidity which, in the
case in point, may not be due solely to the
ageing population process. The morbidity
rate trends in Scotland by urban and rural
areas would be helpful. Traditionally, rates of
use are lower in rural areas for partly
cultural reasons.2 3
Aldo Mariotto director
Primary Health Care Unit Health Authority N 17,
V G Marconi 19, 35043 Monselice (PD), Italy
pghid@libero.it
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Clinical assessment tools need improving
Editor—Murphy et al show some interest-
ing trends in hospital discharge rates from
1990 to 2000 by age: a decline in discharge
rates for acute myocardial infarction and ris-
ing trends for chest pain and angina.1 I agree
with their conclusion, that these trends press
the need for expansion of coronary services.
The rise in chest pain rates needs careful
evaluation as this might represent a trend in
queue jumping in overcrowded hospitals. A
recent study in two urban cardiac referral
centres in Canada has reported a 5% false
negative rate for emergency room clinical
assessment regarding acute coronary syn-
drome.2 Therefore, in view of the serious-
ness of this symptom and high associated
costs of thorough cardiac evaluation, a need
exists for improvement in the clinical assess-
ment tools.
Waseem Sharieff PhD candidate
Hospital for Sick Children, University of Toronto,
555 University Avenue [ 8259, Canada M5G 1X8
doc.sharieff@utoronto.ca
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Authors’ reply
Editor—Mariotto assumes that “new fash-
ioned” elderly people might be more able to
recognise their symptoms and demand their
rights. Although the greatest percentage
change in population rates in each diagnostic
subgroup was in elderly people, the major
increase in absolute numbers of admissions
occurred in those under the age of 75. From
1990 to 2000 the median age of patients
admitted to hospital with a possible acute
coronary syndrome decreased (from 61 to 59
years in men and from 68 to 65 years in
women), as did the median age of patients
admitted with chest pain (from 52 to 51 years
in men and from 56 to 55 years in women).
Sharieff thinks that the rise in emer-
gency admissions might reflect “queue
jumping” (presumably for coronary revascu-
larisation). This seems unlikely over a period
when the waiting time for revascularisation
fell markedly in Scotland.
Niamh Murphy research fellow
John McMurray professor
j.mcmurray@bio.gla.ac.uk
Department of Cardiology, Western Infirmary,
Glasgow G12 8QQ
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Department of Public Health, University of
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Competing interests: None declared.
Tracking system for studies
should be in place
Editor—GlaxoSmithKline’s recent legal
troubles resulting from not publishing nega-
tive results of clinical trials on the antide-
pressant paroxetine are just part of a larger
problem of publication bias in modern
research.1
There has been evidence that the litera-
ture that is published is more likely to be
positive than chance alone might predict.2
There have even been links shown between
positive trials and industry sponsorship.3 But
these cases, although they are alarming,
should not blind us to the general problem
of negative results not being reported.
Proper analysis of new medical treatments
requires properly weighing the evidence for
the new treatment.4
The proper solution to the under-
reporting of negative results is to track all
clinical trials so that we can ensure that the
results of such trials are properly reported. It
is important for both journals and investiga-
tors to work together to ensure that this
occurs. Had such a system been in place, it
would have been much more difficult for
GlaxoSmithKline to conceal these results.
J A C Delaney statistician, clinical epidemiology
Royal Victoria Hospital, R 4.36, 687 Pine Avenue
W, Montreal, QC, Canada H3A 1A1
chris.delaney@clinepi.mcgill.ca
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Prisons show prophylaxis for
close contacts may indeed help
in next flu pandemic
Editor—Balicer et al’s editorial on tackling
the next influenza pandemic highlights the
potential of chemoprophylaxis of close con-
tacts in managing community based influ-
enza pandemics.1 One setting in which such
a strategy shows promise is prisons.
The influenza epidemic in San Quentin
prison in April and May 1918, which
presumably struck 26% of the 1900 prison-
ers, is thought to be one of the primary foci
of the 1918-20 pandemic.2 Documented
outbreaks of flu in prisons have been rare
since then.3 However, our modelling studies
and the limited experience with managing
such a prison outbreak indicate that quaran-
tining clinically ill inmates in their cells or a
health facility and giving antiviral prophy-
laxis to inmates and frontline staff in the
same “wing” of the prison in which the out-
break occurred provide a more favourable
cost benefit than annual mass vaccination,
or a “do nothing” approach.3
In estimating such cost benefits, we took
into consideration the rarity of influenza
outbreaks in prisons (which means “waste-
ful” vaccination in the non-epidemic years),
the high costs of maintaining prisoners’
security in off site settings, the relative
“worthlessness” of prisoners vis à vis
economic valuations of epidemics,4 and the
probably very low mortality among inmates
because of average younger age.
While the World Health Organization
has developed formal strategies for manag-
ing diseases such as tuberculosis in prisons,
currently no formal WHO endorsed guide-
lines exist for influenza. This issue requires
urgent attention.
Niyi Awofeso conjoint associate professor of public
health
University of New South Wales, Sydney, Australia,
Population Health Unit, NSW Corrections Health
Service, PO Box 150, NSW 2036, Australia
niyiawofeso@hotmail.com
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Population discharge rates for acute coronary
syndromes in people over 75 in Scotland1
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